Ms Swati Veera, Head-IPM, Alivus Life Sciences (Formerly Glenmark Life Sciences)

In this video:
Ms Swati Veera, Head-IPM, Alivus Life Sciences (Formerly Glenmark Life Sciences)

Topic: IP strategy for creating innovations in pharma domain

Key Highlights:
[1] IP aids companies to gain and retain its innovation-based advantage. The number of patents owned by a company is used as an indicator for determining innovation intensity of that company

[2] The essence of the pharma industry lies in inventing new drugs that address unmet medical needs, increase longevity, and enhance quality of life. Therefore, patent protection is crucial for this industry

[3] Objective of the offensive patent strategy is to dominate market by preventing competitors from entering the technology area. In defensive patent strategy, patents are filed for creating prior art thereby preventing others from patenting similar inventions